Relying on Xocova alone is not enough. It should be used with other available drugs according to their characteristics to suppress a resurgence of COVID-19.
Shionogi's Xocova is Japan's first domestically produced COVID drug to gain approval for practical use as preparation gear up for the "eighth wave."
Belatedly, Japan is progressing with more support for vaccine research and development, examination and examination for safety and efficacy. Can it catch up?
“What we need the most is an oral drug that can be taken by anyone anywhere…and become a major weapon against COVID-19 alongside vaccines,” says Dr....
Shionogi’s plans involve regional partners and will help supply vaccine across Asia, providing a balance to China’s expansion of its “vaccine diplomacy”.
COVID-19 has shown us pandemics are a national security issue. A new system with leadership needs to be in place to prevent a repeat of Japan’s...
If vaccinations should become necessary every year, the government cannot be sending several hundred billion Japanese yen overseas on an annual basis.
Japan has the technology. Now the government must provide the financial support to bring Japan’s R&D on vaccines and therapeutic drugs up to speed with those...
Many of those living in Japan might be wondering: when will a vaccine become available? What will the logistics look like? And, what should we know...
~The Ministry of Health, Labor and Welfare has set aside ￥137.7 billion JPY ($1.3 billion USD) in subsidies to support companies in Japan that are...
